Healthcare Services

Global Acute Renal Failure (ARF) Market Global Report 2026 Industry Trends and Market Growth Forecast for 2026–2030

March 27, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Acute Renal Failure (ARF) Market By The End Of 2030?

The acute renal failure (arf) market size has demonstrated strong growth in recent years. It is anticipated to expand from $6.6 billion in 2025 to $7.14 billion in 2026, at a compound annual growth rate (CAGR) of 8.3%. This historical growth can be attributed to several factors including the rising prevalence of hypertension and diabetes, increasing hospital-based renal care, limited awareness of early arf symptoms, adoption of conventional dialysis methods, and growth in hospital infrastructure.

The acute renal failure (ARF) market is projected to experience substantial expansion over the upcoming years, with its size expected to reach $9.71 billion by 2030, exhibiting an 8.0% compound annual growth rate (CAGR). This anticipated growth during the forecast period is primarily driven by factors such as the creation of novel nephroprotective medications, the integration of AI-powered diagnostic tools, the broadening availability of home healthcare services, an expanding geriatric population, and increased funding for renal disease research. Key trends expected over this period include a greater embrace of advanced dialysis and renal support therapies, a heightened emphasis on the early detection of acute kidney injury, a surge in the application of nephroprotective drug treatments, the broadening scope of imaging and biopsy-based diagnostic methods, and a growing inclination towards managing ARF patients through home healthcare.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21083&type=smp

What Drivers Are Shaping The Future Growth Of The Acute Renal Failure (ARF) Market?

The expanding occurrence of chronic kidney diseases is anticipated to drive the acute renal failure (ARF) market’s growth moving forward. Chronic Kidney Disease (CKD) is defined as a persistent condition where kidney damage impairs their ability to filter blood effectively. The growing frequency of CKD stems from increasing global rates of diabetes, high blood pressure, obesity, an aging population, and various lifestyle factors. Acute renal failure, marked by an abrupt decline in kidney function, can serve as a major instigator or worsening factor for chronic kidney disease. This occurs by inflicting permanent harm on kidney tissues, reducing filtration capability, and elevating the likelihood of ongoing, prolonged kidney dysfunction if not appropriately treated. An example provided by Kidney Research UK, a non-profit organization in the UK, indicated that in June 2023, around 7.2 million individuals in the UK were affected by chronic kidney disease, accounting for over 10% of the population. Of these, 3.25 million were in advanced stages, while another 3.9 million were in early stages. Projections suggest that by 2033, the total number of people with chronic kidney disease is expected to increase to 7.61 million. Consequently, the rising incidence of chronic kidney diseases is fueling the expansion of the acute renal failure (ARF) market.

Which Segment Classifications Shape The Acute Renal Failure (ARF) Market?

The acute renal failure (arf) market covered in this report is segmented –

1) By Disease Type: Prerenal Acute Renal Failure, Renal Acute Renal Failure, Postrenal Acute Renal Failure

2) By Drug Type: Diuretics, Vasopressors, Erythropoiesis-Stimulating Agents (ESAS), Phosphate Binders, Calcium and Vitamin D Supplements, Antibiotics, Other Drugs

3) By Route of Administration: Oral, Intravenous

4) By End-Users: Clinics, Hospitals, Others End-Users

Subsegments:

1) By Prerenal Acute Renal Failure: Hypovolemia, Decreased Cardiac Output, Renal Artery Stenosis

2) By Renal Acute Renal Failure: Acute Tubular Necrosis, Glomerulonephritis, Interstitial Nephritis

3) By Postrenal Acute Renal Failure: Obstructive Uropathy, Bladder Outlet Obstruction, Kidney Stones

How Are Trends Impacting The Acute Renal Failure (ARF) Market?

Companies operating in the acute renal failure (ARF) market are primarily focused on securing regulatory approvals for their medications, with the goal of expanding their reach and strengthening their position in the treatment of severe acute kidney injury (AKI). Regulatory approvals represent formal authorization from governmental or regulatory bodies, permitting the marketing and public use of drugs, medical devices, or treatments. For example, in February 2024, CalciMedica, a US-based clinical-stage biopharmaceutical company, received FDA approval for an IND application to proceed with a Phase 2 trial of Auxora. This trial aims to evaluate Auxora’s efficacy in addressing severe acute kidney injury (AKI) combined with acute hypoxemic respiratory failure (AHRF), a condition characterized by a high mortality rate. The KOURAGE trial is structured as a randomized, double-blind, placebo-controlled study, planning to enroll approximately 150 patients experiencing Stage 2 and 3 acute kidney injury (AKI) who also suffer from acute hypoxemic respiratory failure (AHRF), assessing Auxora’s effectiveness over five daily doses by measuring the number of days patients remain alive without requiring ventilators or dialysis for up to 30 days post-treatment.

Which Companies Are Expanding Their Footprint In The Acute Renal Failure (ARF) Market?

Major companies operating in the acute renal failure (arf) market are Pfizer Inc, Novartis AG, Baxter International Inc, Fresenius Medical Care AG and Co KGaA, Medtronic plc, Asahi Kasei Corporation, Astellas Pharma Inc, NIKKISO Co Ltd, NIPRO Corporation, Quark Pharmaceuticals Inc, AM Pharma BV, Sentien Biotechnologies, Angion Biomedica Corp, Alloksys Life Sciences BV, Theravance Biopharma, Kissei Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd, B Braun Melsungen AG, Chiesi Farmaceutici SpA, Takeda Pharmaceutical Company Limited

Read the full acute renal failure (arf) market report here:

https://www.thebusinessresearchcompany.com/report/acute-renal-failure-arf-global-market-report

Which Geographic Regions Are Influencing Demand In The Acute Renal Failure (ARF) Market?

North America was the largest region in the acute renal failure (ARF) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute renal failure (arf) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Acute Renal Failure (ARF) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21083&type=smp

Browse Through More Reports Similar to the Global Acute Renal Failure (ARF) Market 2026, By The Business Research Company

kidney disease global market report

https://www.thebusinessresearchcompany.com/report/kidney-disease-global-market-report

kidney dialysis global market report

https://www.thebusinessresearchcompany.com/report/kidney-dialysis-global-market-report

continuous renal replacement therapy global market report

https://www.thebusinessresearchcompany.com/report/continuous-renal-replacement-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795